Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes

References

• Number (in Millions) of civilian, noninstitutionalized persons with diagnosed diabetes, United States, 1980–2014. [cited 2015 Mar 11]. Available from: http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm.
   Google Scholar
• Pafili K, Papanas N, Maltezos E. Treatment of diabetic complications: how can we learn by seeking and blundering? Angiology. 2015;66:301–303.
   PubMed Web of Science ®Google Scholar
• Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370:1514–1523.
   PubMed Web of Science ®Google Scholar
• Anonymous. Diabetes care and research in Europe: the Saint Vincent declaration. Diabet Med. 1990;7:360.
   PubMed Web of Science ®Google Scholar
• Papanas N, Maltezos E, Edmonds M. St. Vincent declaration after 15 years or who cleft the devil’s foot? Vasa. 2006;35:3–4.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2012;35:1364–1379.
   PubMed Web of Science ®Google Scholar
• Pafili K, Papanas N. The importance of patient compliance with insulin pens: how can a new user-friendly pen help? Expert Opin Drug Deliv. 2014;11:629–632.
   PubMed Web of Science ®Google Scholar
• Vlassara H, Striker G. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol. 2011;7:526–539.
   PubMed Web of Science ®Google Scholar
• Pafili K, Papanas N, Maltezos E. Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases? Expert Opin Investig Drugs. 2014;23:1277–1284.
   PubMed Web of Science ®Google Scholar
• Cavelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. 2012;35:1654–1662.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Papanas N, Fonseca VA, et al. Uric acid and diabetes: is there a link? Curr Pharm Des. 2013;19:4930–4937.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Karagiannis A, Mikhailidis DP. Diabetes, bilirubin and amputations: is there a link? Diabetologia. 2013;56:683–685.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Katsiki N, Karagiannis A, et al. Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease. Curr Pharm Des. 2014;20:6299–6305.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
   PubMed Web of Science ®Google Scholar
• Ghosh RK, Ghosh SM, Chawla S, et al. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol. 2012;52:457–463.
   PubMed Web of Science ®Google Scholar
• Blonde L. State of diabetes care in the United States. Am J Manag Care. 2007;13(Suppl 2):S36–40.
   Google Scholar
• Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49) . UK Prospective Diabetes Study (UKPDS) Group. Jama. 1999;281:2005–2012.
   PubMed Web of Science ®Google Scholar
• Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetesa systematic review and meta-analysis. Ann Intern Med. 2013;159:262–267.
   PubMed Web of Science ®Google Scholar
• Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab. 2014;16:433–442.
   PubMed Web of Science ®Google Scholar
• Yang T, Lu M, Ma L, et al. Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis. Eur J Clin Pharmacol. 2015;71:1325–1332.
   PubMed Web of Science ®Google Scholar
• Mearns ES, Sobieraj DM, White CM, et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. PLoS ONE. 2015;10:e0125879.
   PubMed Web of Science ®Google Scholar
• Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:984–993.
   PubMed Web of Science ®Google Scholar
• Berhan A, Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord. 2013;13:58.
   PubMed Web of Science ®Google Scholar
• Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:457–466.
   PubMed Web of Science ®Google Scholar
• Mearns ES, Saulsberry WJ, White CM, et al. Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in type 2 diabetes: a network meta-analysis. Diabet Med. 2015;32:1530–1540.
   PubMed Web of Science ®Google Scholar
• Clar C, Gill JA, Court R, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012;2:e001007.
   PubMed Web of Science ®Google Scholar
• Pafili K, Papanas N. Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time? Expert Opin Pharmacother. 2015;16:453–456.
   PubMed Web of Science ®Google Scholar
• Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016;6:e009417.
   PubMed Web of Science ®Google Scholar
• Matthaei S, Bowering K, Rohwedder K, et al.; Study 05 Group. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015;38:365–372.
   PubMed Web of Science ®Google Scholar
• Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–1380.
   PubMed Web of Science ®Google Scholar
• Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007;320:323–330.
   PubMed Web of Science ®Google Scholar
• Sykes AP, Kemp GL, Dobbins R, et al. Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes. Diabetes Obes Metab. 2015;17:98–101.
   PubMed Web of Science ®Google Scholar
• Licence Agreement of SGLT2 Inhibitor “CSG452” in Japan. [cited 2016 May 06]. Available from: http://www.chugai-pharm.co.jp/hc/ss/downloads/121026eCSG452.pdf?blobheader=application%2Fpdf&blobheadername1=content-disposition&blobheadervalue1=inline%3Bfilename%3D121026eCSG452.pdf&blobwhere=1396858107119&ssbinary=true.
   Google Scholar
• Haas B, Eckstein N, Pfeifer V, et al. Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutr Diabetes. 2014;4:e143.
   PubMed Web of Science ®Google Scholar
• TOFOGLIFLOZIN. [cited 2016 Feb 5]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/tofogliflozin#section=Top.
   Google Scholar
• (1S,3ʹR,4’S,5’S,6ʹR)-6-(4-Ethylbenzyl)-6ʹ-(hydroxymethyl)-3ʹ,4ʹ,5ʹ,6ʹ-tetrahydro-3H-spiro[2-benzofuran-1,2ʹ-pyran]-3ʹ,4ʹ,5ʹ-triol. [cited 2016 Apr 20]. Available from: http://www.chemspider.com/Chemical-Structure.28530778.html
   Google Scholar
• Sato T, Kobayashi T, Nishimoto M, et al. (2010) Discovery of O-spiroketal C-arylglucosides as novel and selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Scientific Abstracts for the 240th National ACS Meeting and Exposition; 2010 Aug 22–26; Boston, MA. Washington, DC: American Chemical Society; p. MEDI–202.
   Google Scholar
• Compound report card. [cited 2016 Apr 20]. Available from: https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2110731.
   Google Scholar
• Efficay of SGLT2 inhibitors on bone mineral density in Japanese patients with type 2 diabetes. [cited 2016 Aug 21]. Available from: http://www.easdvirtualmeeting.org/resources/efficacy-of-sglt2-inhibitors-on-bone-mineral-density-in-japanese-patients-with-type-2-diabetes–3.
   Google Scholar
• Ishibashi Y, Matsui T, Yamagishi S. Tofogliflozin, a highly selective inhibitor of sglt2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm Metab Res. 2016;48:191–195.
   PubMed Web of Science ®Google Scholar
• Sugaru E, Nakagawa T, Ono-Kishino M, et al. Enhanced effect of combined treatment with SMP-534 (antifibrotic agent) and losartan in diabetic nephropathy. Am J Nephrol. 2006;26:50–58.
   PubMed Web of Science ®Google Scholar
• Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509–514.
   PubMed Web of Science ®Google Scholar
• Cohen JJ, Berglund F, Lotspeich WD. Renal tubular reabsorption of acetoacetate, inorganic sulfate and inorganic phosphate in the dog as affected by glucose and phlorizin. Am J Physiol. 1956;184:91–96.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Honda K, Fukazawa M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012;341:692–701.
   PubMed Web of Science ®Google Scholar
• Nagata T, Fukuzawa T, Takeda M, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol. 2013;170:519–531.
   PubMed Web of Science ®Google Scholar
• Tahara A, Takasu T, Yokono M, et al. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J Pharmacol Sci. 2016;130:159–169.
   PubMed Web of Science ®Google Scholar
• Ikeda S, Takano Y, Cynshi O, et al. A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:984–993.
   PubMed Web of Science ®Google Scholar
• Devenny JJ, Godonis HE, Harvey SJ, et al. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring). 2012;20:1645–1652.
   PubMed Web of Science ®Google Scholar
• Liang Y, Arakawa K, Ueta K, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One. 2012;7:e30555.
   PubMed Web of Science ®Google Scholar
• Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65.
   PubMed Web of Science ®Google Scholar
• Pafili K, Papanas N. Tofogliflozin: the road goes ever on. Expert Opin Pharmacother. 2014;15:1197–1201.
   PubMed Web of Science ®Google Scholar
• Tanizawa Y, Kaku K, Araki E, et al. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother. 2014;15:749–766.
   PubMed Web of Science ®Google Scholar
• Zhang L, Feng Y, List J, et al. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010;12:510–516.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Ikeda S, Takano Y, et al. Tofogliflozin, a novel and selective SGLT2 inhibitor improves glycemic control and lowers body weight in patients with type 2 diabetes mellitus inadequately controlled on stable metformin or diet and exercise alone. Diabetes. 2012;61(Suppl. 1):A22.
   Google Scholar
• Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405–415.
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Ferrannini E, Wilding JP, et al. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications. 2013;27:268–273.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36:2508–2515.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Takeda M, Kito A, et al. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes. 2014;4:e125.
   PubMed Web of Science ®Google Scholar
• Sengupta P. The laboratory rat: relating its age with human’s. Int J Prev Med. 2013;4:624–630.
   PubMedGoogle Scholar
• Obata A, Kubota N, Kubota T, et al. Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice. Endocrinology. 2016;157:1029–1042.
   PubMed Web of Science ®Google Scholar
• Finlay BL, Darlington RB. Linked regularities in the development and evolution of mammalian brains. Science. 1995;268:1578–1584.
   PubMed Web of Science ®Google Scholar
• Jurczak MJ, Lee H-Y, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011;60:890–898.
   PubMed Web of Science ®Google Scholar
• Ojima A, Matsui T, Nishino Y, et al. Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm Metab Res. 2015;47:686–692.
   PubMed Web of Science ®Google Scholar
• Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells–renoprotection in diabetic nephropathy? PLoS One. 2013;8:e54442.
   PubMed Web of Science ®Google Scholar
• Breyer MD, Böttinger E, Brosius FC 3rd, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2005;16:27–45.
   PubMed Web of Science ®Google Scholar
• Soler MJ, Riera M, Batlle D. New experimental models of diabetic nephropathy in mice models of type 2 diabetes: efforts to replicate human nephropathy. Exp Diabetes Res. 2012;2012:616313.
   PubMedGoogle Scholar
• Ohtake Y, Sato T, Kobayashi T, et al. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2012;55:7828–7840.
   PubMed Web of Science ®Google Scholar
• Yamane M, Kawashima K, Yamaguchi K, et al. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP. Xenobiotica. 2015;45:230–238.
   PubMed Web of Science ®Google Scholar
• Schwab D, Portron A, Backholer Z, et al. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans. Clin Pharmacokinet. 2013;52:463–473.
   PubMed Web of Science ®Google Scholar
• Zell M, Husser C, Kuhlmann O, et al. Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans. Xenobiotica. 2014;44:369–378.
   PubMed Web of Science ®Google Scholar
• SGLT2 inhibitor versus sulfonylurea on type 2 diabetes with NAFLD. [cited 2016 May 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT02649465?intr=%22Tofogliflozin%22+OR+%22Csg452%22%2C+%22TOFOGLIFLOZIN%22&rank=3.
   Google Scholar
• Metabolic and cardiovascular effects of dipeptidyl peptidase-4 (DPP-4) or sodium-glucose co-transporter type 2 (SGLT2) inhibitors. [cited 2016 Feb 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT02528019?intr=%22Tofogliflozin%22+OR+%22Csg452%22%2C+%22TOFOGLIFLOZIN%22&rank=4.
   Google Scholar
• Meta-analysis in post-marketing surveillances for SGLT2 inhibitors in patients with type 2 diabetes mellitus. [cited 2016 Feb 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT02284269?intr=%22Tofogliflozin%22+OR+%22Csg452%22%2C+%22TOFOGLIFLOZIN%22&rank=5.
   Google Scholar
• Athyros VG, Tziomalos K, Katsiki N, et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update. World J Gastroenterol. 2015;21:6820–6834.
   PubMed Web of Science ®Google Scholar
• Tofogliflozin GLP-1 analogue combination trial. [cited 2016 May 4]. Avaialble from: https://clinicaltrials.gov/ct2/show/record/NCT02537834?intr=%22Tofogliflozin%22+OR+%22Csg452%22%2C+%22TOFOGLIFLOZIN%22&rank=1.
   Google Scholar
• TOFO insulin combination trial. [cited 2016 May 4]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02201004?intr=%22Tofogliflozin%22+OR+%22Csg452%22%2C+%22TOFOGLIFLOZIN%22&rank=2.
   Google Scholar
• Yamaguchi K, Kato M, Suzuki M, et al. In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach. J Pharmacol Exp Ther. 2013;345:52–61.
   PubMed Web of Science ®Google Scholar
• Nagata T, Fukazawa M, Honda K, et al. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. Am J Physiol Endocrinol Metab. 2013;304:E414–23.
   PubMed Web of Science ®Google Scholar
• Nagata T, Suzuki M, Fukazawa M, et al. Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys. Am J Physiol Renal Physiol. 2014;306:F1520–33.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Kato M, Ozawa K, et al. Pharmacokinetic and pharmacodynamic modeling for the effect of sodium-glucose cotransporter inhibitors on blood glucose level and renal glucose excretion in db/db mice. J Pharm Sci. 2012;101:4347–4356.
   PubMed Web of Science ®Google Scholar
• Europe, US, Japan: the recall round-up. [cited 2016 May 6]. Available from: http://www.in-pharmatechnologist.com/Regulatory-Safety/Europe-US-Japan-The-recall-round-up.
   Google Scholar
• Summary of investigation results. Sodium-glucose co-transporter 2 (SGLT2) inhibitors. [cited 2016 May 6] Available from: https://www.pmda.go.jp/files/000207393.pdf.
   Google Scholar
• Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J-STEP/EL): A 12-week interim analysis. [cited 2015 May 6]. Available from: http://onlinelibrary.wiley.com/doi/10.1111/jdi.12513/pdf.
   Google Scholar
• Gibbs EM, Stock JL, McCoid SC, et al. Glycemic improvement in diabetic db/db mice by overexpression of the human insulin-regulatable glucose transporter (GLUT4). J Clin Invest. 1995;95:1512–1518.
   PubMed Web of Science ®Google Scholar
• Lenhard JM, Lancaster ME, Paulik MA, et al. The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction. Diabetologia. 1999;42:545–554.
   PubMed Web of Science ®Google Scholar
• Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab. 2013;15:1136–1145.
   PubMed Web of Science ®Google Scholar
• Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372–382.
   PubMed Web of Science ®Google Scholar
• Kaku K, Inoue S, Matsuoka O, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a Phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2013;15:432–440.
   PubMed Web of Science ®Google Scholar
• Washburn WN, Poucher SM. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs. 2013;22:463–486.
   PubMed Web of Science ®Google Scholar
• Chao EC, Henry RR. SGLT2 inhibition— a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9:551–559.
   PubMed Web of Science ®Google Scholar
• Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733–794.
   PubMed Web of Science ®Google Scholar
• Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22:104–112.
   PubMed Web of Science ®Google Scholar
• Hummel CS, Lu C, Loo DD, et al. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol. 2011;300:C14–21.
   PubMed Web of Science ®Google Scholar
• Liu JJ, Lee T, DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes. 2012;61:2199–2204.
   PubMed Web of Science ®Google Scholar
• Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol. 2011;300:R1009–22.
   PubMed Web of Science ®Google Scholar
• Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85:520–526.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Hompesch M, Kasichayanula S, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013;36:3169–3176.
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012;44:375–393.
   PubMed Web of Science ®Google Scholar
• Patel AK, Fonseca V. Turning glucosuria into a therapy: efficacy and safety with SGLT2 inhibitors. Curr Diabetes Rep. 2010;10:101–107.
   PubMed Web of Science ®Google Scholar
• Hussey EK, Dobbins RL, Stoltz RR, et al. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. J Clin Pharmacol. 2010;50:636–646.
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. [cited 2016 Mar 2]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm.
   Google Scholar
• EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes. [cited 2016 Mar 2]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/SGLT2_inhibitors/human_referral_prac_000052.jsp&mid=WC0b01ac05805c516f.
   Google Scholar
• Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849–2852.
   PubMed Web of Science ®Google Scholar
• Singh AK. Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: wisdom of hindsight. Indian J Endocrinol Metab. 2015;19:722–730.
   PubMedGoogle Scholar
• Kalra S, Sahay R, Gupta Y. Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis. Indian J Endocrinol Metab. 2015;19:524–528.
   PubMedGoogle Scholar
• Yokono M, Takasu T, Hayashizaki Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol. 2014;727:66–74.
   PubMed Web of Science ®Google Scholar
• Fukao T, Lopaschuk GD, Mitchell GA. Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry. Prostaglandins Leukot Essent Fatty Acids. 2004;70:243–251.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499–508.
   PubMed Web of Science ®Google Scholar
• Martin PM, Gopal E, Ananth S, et al. Identity of SMCT1 (SLC5A8) as a neuron-specific Na-coupled transporter for active uptake of L-lactate and ketone bodies in the brain. J Neurochem. 2006;98:279–288.
   PubMed Web of Science ®Google Scholar
• Ruderman NB, Ross PS, Berger M, et al. Regulation of glucose and ketone-body metabolism in brain of anaesthetized rats. Biochem J. 1974;138:1–10.
   PubMed Web of Science ®Google Scholar
• Nishimura R, Osonoi T, Jinnouchi H, et al. Low carbohydrate did not affect the behaviour of luseogliflozin, a selective SGLT2 inhibitor on glycemic control over 24 hours measured by continuous glucose monitoring in Japanese patients with type 2 diabetes. Poster Presentation. American Diabetes Association Meeting, Boston; 2015. p. 948.
   Google Scholar
• Nakayama H, Yoshinobu S, Kawano S, et al. Factors associated with the effect of ipragliflozin on the diurnal profiles of plasma glucose and 3-hydroxybutyrate in patient with type 2 diabetes. Poster Presentation. American Diabetes Association Meeting, Boston; 2015. p. 1236.
   Google Scholar
• Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512–517.
   PubMed Web of Science ®Google Scholar
• Ferrannini E. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care. 2010;33:2217–2224.
   PubMed Web of Science ®Google Scholar
• List JF, Woo V, Morales E, et al. Sodium glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650–657.
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. [cited 2015 Jun 1]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm.
   Google Scholar
• Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–971.
   PubMed Web of Science ®Google Scholar
• Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015;3:8–10.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2016 executive summary. Endocr Pract. 2016;22:84–113.
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015;21(Suppl 1):1–87.
   PubMed Web of Science ®Google Scholar
• Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015;38:412–419.
   PubMed Web of Science ®Google Scholar
• Perkins BA, Cherney DZ, Partridge H, et al. Sodiumglucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37:1480–1483.
   PubMed Web of Science ®Google Scholar